Romano Gennaro1, Davide Barletta2, Gianni Paulis3. 1. Department of Urologic Oncology, Section of Avellino, Italian League Against Cancer, Avellino, Italy. info@gennaroromano.it. 2. Department of Urology, San Matteo Hospital - IRCCS, Pavia, Italy. barletta_dave@yahoo.it. 3. Center of Andrology, Regina Apostolorum Hospital, Albano Laziale, Rome, Italy. paulisg@libero.it.
Abstract
OBJECTIVE: The significantly different effects of several conservative treatments for Peyronie's disease (PD) led us to conduct this study to evaluate the effectiveness of local treatment with injectable hyaluronic acid (HA) for patients with this disease. MATERIALS AND METHODS: The study included 83 PD patients who underwent treatment and 81 PD patients who did not (control group). The inclusion criteria were: penile plaque volume <1 cm(3); clinical characteristics and ultrasonographic appearance compatible with active inflammation; and penile curvature <45°. The medical history of all PD patients was collected. Patients undertook six tests: routine laboratory tests; penile auto-photography during erection; dynamic penile colour-duplex ultrasound study; penile X-ray (mammography technique); index of erectile function questionnaire (IIEF); and pain intensity questionnaire (visual analog scale). Treated patients received thirty penile infiltrations by injection of 20 mg HA in 6 months. Follow-up checks were conducted at the end of treatment and 12 and 24 months after treatment. RESULTS: At 12-month follow-up all treated PD patients had experienced three statistically significant outcomes: reduction in plaque size (-93.7 %, p < 0.0001); improvement in penile curvature (-9.01°, p < 0.0001); and improvement in penile rigidity (mean IIEF score +3.8) with an average increase of 21.1 % (p < 0.0001). Furthermore, the improvements remained substantially stable at 24-month follow-up. CONCLUSION: Considering the minimally invasive approach in this study, the absence of major side effects, and the significant treatment outcomes achieved, we conclude that intralesional penile injections with HA are effective for treating Peyronie's disease.
OBJECTIVE: The significantly different effects of several conservative treatments for Peyronie's disease (PD) led us to conduct this study to evaluate the effectiveness of local treatment with injectable hyaluronic acid (HA) for patients with this disease. MATERIALS AND METHODS: The study included 83 PDpatients who underwent treatment and 81 PDpatients who did not (control group). The inclusion criteria were: penile plaque volume <1 cm(3); clinical characteristics and ultrasonographic appearance compatible with active inflammation; and penile curvature <45°. The medical history of all PDpatients was collected. Patients undertook six tests: routine laboratory tests; penile auto-photography during erection; dynamic penile colour-duplex ultrasound study; penile X-ray (mammography technique); index of erectile function questionnaire (IIEF); and pain intensity questionnaire (visual analog scale). Treated patients received thirty penile infiltrations by injection of 20 mg HA in 6 months. Follow-up checks were conducted at the end of treatment and 12 and 24 months after treatment. RESULTS: At 12-month follow-up all treated PDpatients had experienced three statistically significant outcomes: reduction in plaque size (-93.7 %, p < 0.0001); improvement in penile curvature (-9.01°, p < 0.0001); and improvement in penile rigidity (mean IIEF score +3.8) with an average increase of 21.1 % (p < 0.0001). Furthermore, the improvements remained substantially stable at 24-month follow-up. CONCLUSION: Considering the minimally invasive approach in this study, the absence of major side effects, and the significant treatment outcomes achieved, we conclude that intralesional penile injections with HA are effective for treating Peyronie's disease.
Authors: Laurence A Levine; Beatrice Cuzin; Stephen Mark; Martin K Gelbard; Nigel A Jones; Genzhou Liu; Gregory J Kaufman; James P Tursi; David J Ralph Journal: J Sex Med Date: 2014-11-12 Impact factor: 3.802
Authors: Martin Gelbard; Irwin Goldstein; Wayne J G Hellstrom; Chris G McMahon; Ted Smith; James Tursi; Nigel Jones; Gregory J Kaufman; Culley C Carson Journal: J Urol Date: 2013-01-31 Impact factor: 7.450
Authors: Can Tuygun; Ugur Hakki Ozok; Adnan Gucuk; I Halil Bozkurt; M Abdurrahim Imamoglu Journal: Int Urol Nephrol Date: 2008-07-01 Impact factor: 2.370
Authors: William P Fitch; W Jerry Easterling; Robert L Talbert; Michael J Bordovsky; Michael Mosier Journal: J Sex Med Date: 2007-03 Impact factor: 3.802
Authors: Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock Journal: Can Urol Assoc J Date: 2018-02-22 Impact factor: 1.862
Authors: Andrea Cocci; Fabrizio Di Maida; Gianmartin Cito; Pierangelo Verrienti; Nicola Laruccia; Riccardo Campi; Andrea Mari; Marina Di Mauro; Marco Falcone; Giovanni E Cacciamani; Giulio Garaffa; Andrea Minervini; Giorgio Ivan Russo Journal: World J Mens Health Date: 2020-01-20 Impact factor: 5.400
Authors: Gianni Paulis; Davide Barletta; Paolo Turchi; Antonio Vitarelli; Giuseppe Dachille; Andrea Fabiani; Romano Gennaro Journal: Res Rep Urol Date: 2015-12-31